Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs

Anti-neoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. However, these drugs are harmful to healthy cells as well as the cancerous cells. Exposure of healthcare workers to anti-neoplastic drugs from contaminated surfaces and drug vials in hospitals and pharmacies is a continuing problem as the drugs can cause both acute and long-term effects. Although there are sensitive techniques to evaluate contamination, results from these tests take time and must be performed in a laboratory. CDC researchers developed a real-time detection kit that can be used in the workplace to test for anti-neoplastic drug contamination. The direct reading anti-neoplastic drug detector based on lateral flow immunoassay (LFIA) technology has been developed for the assessment of drug residues on surfaces. These detectors are incorporated into kits that allow workers to sample surfaces to assess drug contamination in near real-time. Detection kits for three anti-neoplastic drugs (5-Fluorouracil, Paclitaxel, and Doxorubicin) have been developed and kits for several other anti-neoplastic agents may be possible based on this technology.

Potential Commercial Applications: Competitive Advantages:
  • Environmental sampling / detection kit for surface contamination by anti-neoplastic (anti-cancer) drugs in hospitals and pharmacies
  • Kits can be used to assess decontamination procedures
  • Kits can be used to assess protective equipment and closed system drug-transfer devices
  • Kits can aid in the development of work practices to lower healthcare worker exposure to anti-neoplastic drugs from contaminated surfaces
  • Near real-time results
  • Can be used in various locations, on surfaces, and on protective equipment
  • Simple to use
  • Final kit configuration to incorporate laboratory and field studies for maximum benefit to healthcare workers


Deborah Sammons (CDC)  ➽ more inventions...

Jerome Smith (CDC)  ➽ more inventions...

Shirley Robertson (CDC)  ➽ more inventions...

Intellectual Property:
US Application No. 61/672,059
PCT Application No. PCT/US2013/050688
US Application No. 13/943,430
Foreign counterpart patent applications in Europe and Japan.

Smith JP PMID 25293722
Smith JP PMID 25379615
Smith JP PMID 25956418

Collaboration Opportunity:

The CDC/NIOSH is seeking statements of capability or interest from parties interested in collaborative reasearch to further develop, evaluate, or commercialize Detection Kits for Surface Contamination by Anti-Neoplastic Drugs. For collaboration opportunities, please contact Kathleen Goedel at or 1-513-533-8686.

Licensing Contact:
Karen Surabian, J.D., M.B.A.
Phone: 301-594-9719

OTT Reference No: E-162-2013-0
Updated: Aug 31, 2017